Trials / Conditions / Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Hodgkin Lymphoma
5 registered clinical trials studyying Ann Arbor Stage III Hodgkin Lymphoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly NCT03907488 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma NCT02758717 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin NCT01771107 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |